FATE - Fate Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
16.05
-0.73 (-4.35%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close16.78
Open16.89
Bid15.10 x 800
Ask17.09 x 1000
Day's Range16.03 - 17.14
52 Week Range4.13 - 17.98
Volume648,554
Avg. Volume843,938
Market Cap1.037B
Beta (3Y Monthly)4.06
PE Ratio (TTM)N/A
EPS (TTM)-1.24
Earnings DateMar 4, 2019 - Mar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.43
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new preclinical data on the Company’s induced pluripotent stem cell (iPSC) product platform and its iPSC-derived, off-the-shelf cell-based cancer immunotherapy pipeline at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition. Last week, the Company announced that the U.S. Food and Drug Administration (FDA) allowed its Investigational New Drug (IND) Application for FT500, the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master iPSC line.

  • GlobeNewswire10 days ago

    Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products

    Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has secured an exclusive option to an intellectual property portfolio owned by the Max Delbrück Center for Molecular Medicine (MDC) covering novel humanized chimeric antigen receptor (CAR) constructs that uniquely and specifically bind B-cell Maturation Antigen (BCMA). Under the agreement with MDC, Fate Therapeutics holds an exclusive option to exclusively license the portfolio for all cell products, including CAR NK- and T-cell products, derived from induced pluripotent stem cells (iPSCs).

  • Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%
    Zacks11 days ago

    Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%

    Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • GlobeNewswire11 days ago

    Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE14 days ago

    How Healthcare Is Evolving & Sector Stocks To Watch

    CORAL GABLES, FL / ACCESSWIRE / November 30,2018 / The Global Connected Healthcare Market was valued at USD $1,860.26 million in2017, and is expected to grow at a CAGR of 28.3% by 2025. There has been a growing increase in the use of smartphones by physicians leading to a practice of digital health. The global digital health market is expanding at a fast pace.

  • MarketWatch14 days ago

    Shares of Fate Therapeutics up 4.1% in premarket trade after FDA accepts IND application for potential cancer treatment

    Shares of Fate Therapeutics were up 4.1% in premarket trade Friday after the company announced the U.S. Food and Drug Administration had accepted its investigational new drug application for FT500, a potential natural killer cell cancer immunotherapy for advanced tumors. The study is expected to evaluate the safety and tolerability of multiple doses of the drug alone and in combination with other therapies like nivolumab, pembrolizumab or atezolizumab in subjects where checkpoint inhibitor treatments haven't worked. Shares of Fate Therapeutics, a small-cap clinical-stage biopharmaceutical company, have gained 131% in the year to date, while the S&P 500 has gained 2.4%.

  • 3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer
    Investor's Business Daily15 days ago

    3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer

    The American Society of Hematology meeting could "bring some excitement" this weekend in San Diego as biopharma giants take their blood cancer treatments to bat.

  • What Kind Of Shareholder Appears On The Fate Therapeutics Inc’s (NASDAQ:FATE) Shareholder Register?
    Simply Wall St.28 days ago

    What Kind Of Shareholder Appears On The Fate Therapeutics Inc’s (NASDAQ:FATE) Shareholder Register?

    Every investor in Fate Therapeutics Inc (NASDAQ:FATE) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...

  • GlobeNewswirelast month

    Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500

    SAN DIEGO, Nov. 11, 2018 (GLOBE NEWSWIRE) --  Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new clinical data for FATE-NK100, an investigational, first-in-class, allogeneic donor-derived natural killer (NK) cell cancer immunotherapy, and provided a regulatory update on the development of FT500, a universal, off-the-shelf NK cell product candidate derived from a master induced pluripotent stem cell (iPSC) line, on November 10, 2018. Twenty heavily pre-treated subjects, each presenting with progressive disease at the time of enrollment, have been treated with FATE-NK100 in the dose-escalation phases of three Phase 1 clinical trials.

  • GlobeNewswirelast month

    Fate Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 08, 2018 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of FATE earnings conference call or presentation 1-Nov-18 9:00pm GMT

    Q3 2018 Fate Therapeutics Inc Earnings Call

  • Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates
    Zackslast month

    Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates

    Fate Therapeutics (FATE) delivered earnings and revenue surprises of -29.17% and -72.98%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Fate Therapeutics: 3Q Earnings Snapshot

    The San Diego-based company said it had a loss of 31 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a ...

  • GlobeNewswirelast month

    Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress

    Twenty Subjects Treated across Three Phase 1 Studies of FATE-NK100 Entered into Off-the-Shelf, iPSC-derived CAR-T Cell Collaboration with ONO Pharmaceutical Completed.

  • GlobeNewswirelast month

    Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting

    Three Oral and Four Poster Presentations Covering Product Pipeline Accepted for Presentation Company to Host Investor Event at ASH on November 30 SAN.

  • GlobeNewswirelast month

    Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results

    SAN DIEGO, Oct. 29, 2018 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer.

  • ACCESSWIRE2 months ago

    3 Healthcare Stocks To Watch On Thursday

    CORAL GABLES, FL / ACCESSWIRE / October 25,2018 / Healthcare stocks have helped to boost the US equity markets today. The Select Sector SPDR Healthcare ETF (XLV) has had a strong recovery on Thursday and the broader markets are also surging. The healthcare industry has seen a shakeup recently as new technology innovation and further research on new drugs pushes industry margins.

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for Workhorse Group, Fate Therapeutics, Minerals Technologies, Tyson Foods, ZAGG, and USA Technologies — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations

    Fate Therapeutics, Inc. (FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Wen Bo Wang, Ph.D., a leading expert in the manufacture of pluripotent stem cell-derived cell products, has joined the Company as Senior Vice President, Technical Operations. Dr. Wang brings to Fate Therapeutics more than 18 years of cell therapy leadership, having most recently served as Senior Vice President, Cell Therapy Research & Development at FUJIFILM Cellular Dynamics, Inc. Dr. Wang will be responsible for shaping the Company’s manufacturing strategies for its pipeline of off-the-shelf cell-based cancer immunotherapy candidates and scaling the Company’s induced pluripotent stem cell (iPSC) product platform to support late-stage clinical and commercial operations.

  • Barrons.com2 months ago

    This Biotech Stock Has Quadrupled — and Its Top Shareholder Is Still Buying

    Fate Therapeutics has quadrupled in the past 12 months and has more than doubled this year. Top shareholder Redmile Group still wanted to buy more.

  • GlobeNewswire3 months ago

    Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of 10,648,149 shares of its common stock, which included 1,388,889 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $13.50 per share. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of clinical product candidates and the conduct of preclinical research and development, and for general corporate purposes. Jefferies, Piper Jaffray, and Wells Fargo Securities acted as joint book-running managers for the offering.

  • GlobeNewswire3 months ago

    Fate Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, Sept. 25, 2018-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...

  • GlobeNewswire3 months ago

    Fate Therapeutics Announces Pricing of Public Offering of Common Stock

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of 9,259,260 shares of its common stock at a public offering price of $13.50 per share, before underwriting discounts, for an aggregate offering of approximately $125.0 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,388,889 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected to be approximately $117.2 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters’ option.

  • GlobeNewswire3 months ago

    Fate Therapeutics Announces Proposed Public Offering of Common Stock

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of its common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of clinical product candidates and the conduct of preclinical research and development, and for general corporate purposes. All shares of common stock to be sold in the offering will be offered by Fate Therapeutics.